A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis

A Phase 2, Open-label Extension Study to Evaluate the Long-Term Safety, Clinical Activity, and Pharmacokinetics of ALN-TTRSC in Patients With Transthyretin (TTR) Cardiac Amyloidosis Who Have Previously Received ALN-TTRSC

The purpose of this study was to evaluate the safety and clinical activity of long-term dosing with revusiran (ALN-TTRSC). Dosing has been discontinued; patients are being followed-up for safety.

Inclusion Criteria:

• Subjects who previously received and tolerated revusiran (ALN-TTRSC) in the ALN-TTRSC-002 study
• Adequate liver function
• Not Pregnant or nursing

Exclusion Criteria:

• Inadequate renal function
• Uncontrolled hypertension, ischemic heart disease or clinically significant cardiac arrhythmia
• Untreated hypo- or hyperthyroidism
• Prior major organ transplant